Erbitux cleared for first-line colorectal cancer use in Japan
This article was originally published in Scrip
Executive Summary
Lilly (ImClone Systems)/Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) has been approved in Japan for the first-line treatment of selected metastatic colorectal cancer patients.